CCM
GILD icon

Callodine Capital Management’s Gilead Sciences GILD Stock Holding History

Callodine Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-76,700
Closed -$5.57M – 49
2021
Q4 		$5.57M Hold
76,700
– – 2.16% 22
2021
Q3 		$5.36M Buy
+76,700
New +$5.39M 2.02% 22

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Callodine Capital Management's GILD Position: Q1 2022 in Review

Callodine Capital Management sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 40,000 shares — an estimated $2.9M sold.

Callodine Capital Management first reported a position in GILD in Q1 2021 and held it in 4 quarters. The position peaked at $9.64M in Q2 2021. 1,601 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

  • Callodine Capital Management reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
  • Callodine Capital Management sold 40,000 Gilead Sciences shares in Q1 2022, an estimated $2.9M.
  • Callodine Capital Management first reported a position in Gilead Sciences in Q1 2021 and held it in 4 quarters.
  • Callodine Capital Management's Gilead Sciences position peaked at $9.64M in Q2 2021.
  • 1,601 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Callodine Capital Management's 13F filing for Q1 2022, filed 13 May 2022.